About ViaCord
ViaCord is a Healthcare company based in Hebron (United States) founded in 1993 by Cynthia Fisher, and was acquired by PerkinElmer in October 2007. Provider of services for cord blood and stem cell banking. ViaCord has raised $84.5 million across 3 funding rounds from investors including Amgen, PerkinElmer and Nomura. Its website viacord.com draws about 101 thousand monthly visits. ViaCord offers products and services including Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
ViaCord was founded in 1993 in Hebron, United States, within the healthcare and biotechnology sectors. Cord blood from newborns umbilical cords is collected and stored by the company for potential future treatments of conditions like leukemias, immune deficiencies, and metabolic disorders. Genetic testing services are also made available to support therapeutic choices. Operations center on family preservation programs across the United States.
- Headquarters Hebron, United States
- Founders Cynthia Fisher
- Stage Acquired
- SectorsHealthcare
- Website category Health · Womens Health
- Email••••••••
- Phone•••• ••••
- Website viacord.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by PerkinElmer (Oct 2007)
- Total Equity Funding$84.5M (USD)
in 3 rounds
- Latest Funding Round$20M (USD), Series C
Dec 2003
- InvestorsAmgen
& 8 more
- Acquired byPerkinElmer
(Oct 2007)
Products & Services of ViaCord
ViaCord offers a comprehensive portfolio of products and services, including Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing.
Service to collect and store umbilical cord blood stem cells.
Preserves cord tissue for potential regenerative treatments.
Analyzes genes for actionable health conditions in newborns.
Sequences genes to identify health risks and drug sensitivities.
Apps and channels of ViaCord
its YouTube channel ViaCord Videos has 613 subscribers and 17 videos.
Videos from ViaCord
The most watched videos on ViaCord's YouTube channel, ViaCord Videos (613 subscribers). Click a video to play it here.
More on ViaCord Videos.
Funding Insights of ViaCord
ViaCord has successfully raised a total of $84.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in December 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84.5M
- Total Rounds 3
- Last Round Series C — $20M
- First Round $48M
(Nov 2000)
- Investors Count 8
All 3 funding rounds of ViaCord with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2003 | $20M | Series C | – | – | |
| Feb 2002 | $16.5M | Series C | – | – | |
| Nov 2000 | $48M | Series C | – | – |
9 investors in total: 9 institutional.
Investors in ViaCord
ViaCord has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, PerkinElmer and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | stephensgroup.com | Little Rock, United States | ||
| zerostage.com | ||||
Healthcare investments are made by Tullis Health Investors. | tullisfunds.com | Palm Beach Gardens, United States | ||
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Serves as a government agency dedicated to fostering business development and growth in Singapore. | 1961 | edb.gov.sg | Singapore, Singapore | |
Diversified asset management services are offered globally by the firm. | 1925 | nomura.com | Chuo City, Japan | |
Biopharmaceutical products for rare genetic diseases are developed and supplied. | 1996 | genzyme.com | Boston, United States | |
Manages diversified investment portfolios across various asset classes. | 2015 | deutscheam.com | Frankfurt, Germany | |
Medical instruments and supplies are manufactured and provided for healthcare. | 1931 | perkinelmer.com | Waltham, United States |
Investor details for ViaCord
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ViaCord
1 people are tracked at ViaCord (1 in leadership).
| Name | Role | Group |
|---|---|---|
Cynthia Fisher | Founder | Leadership |
Complete people profiles for ViaCord
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ViaCord
4 dated milestones of ViaCord across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ViaCord is founded.
- Funding First funding round of $48.0M.
- Funding Latest funding round, Series C, of $20.0M.
- Exit Acquired by PerkinElmer.
Competitors of ViaCord
ViaCord has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of ViaCord
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ViaCord
The website of ViaCord (viacord.com) receives about 100.7K visits a month and ranks #263,080 among all websites worldwide, #8,925 in Womens Health.
- Monthly visits100.7K
▼ 42.8% vs previous month
- Unique visitors88.8K
per month
- Global rank#263,080
among all websites
- Category rank#8,925
Health · Womens Health
- Bounce rate48%
- Pages per visit2.0
- Average visit2 min 16 sec
- DevicesDesktop 4% · Mobile 96%
Websites whose visitors overlap most with ViaCord. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| americordblood.com | 100% | #244,562 | View details | ||
| miraclecord.com | 97% | 69.8K | #575,258 | View details | |
| joinmidi.com | 97% | 1M | #50,615 | View details | |
9monate.qualimedic.de | 9monate.qualimedic.de | 92% | – | ||
| ntdlabs.com | 92% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for ViaCord
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ViaCord (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viacord
Complete news archive for ViaCord
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaCord
ViaCord was founded in 1993 and raised its 1st funding round 7 years after it was founded.
ViaCord is headquartered in Hebron, United States. It is registered at Hebron, Connecticut, United States.
ViaCord is a funded company, having raised a total of $84.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $48M, raised on Nov 2000.
ViaCord was founded in 1993 in Hebron, United States, within the healthcare and biotechnology sectors. Cord blood from newborns umbilical cords is collected and stored by the company for potential future treatments of conditions like leukemias, immune deficiencies, and metabolic disorders. Genetic testing services are also made available to support therapeutic choices. Operations center on family preservation programs across the United States.
ViaCord's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
ViaCord offers Cord Blood Banking, Cord Tissue Banking, Genetic Insight Panel, and Whole Genome Sequencing.
ViaCord has 9 investors. Key investors include Amgen, PerkinElmer, Nomura, Genzyme, and Singapore Economic Development Board.
Yes. ViaCord was acquired by PerkinElmer in October 2007.
The website of ViaCord receives about 101 thousand visits a month and ranks #263,080 among all websites worldwide.